All TreatGx users now have access to the updated treatment algorithms for Acute Gout and Peripheral Artery Disease. As always, both of these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. Acute Gout This…
Jared spoke with us on the Precision Insights podcast about telehealth, and how it has been affected by the COVID-19 pandemic, along with his predictions for the future of telehealth. What follows is a summary of the discussion we had with him; the full podcast can be accessed here.
All TreatGx users now have access to the updated treatment algorithms for Depression, Heart Failure – Fluid Retention, Chronic Pain – Trigeminal Neuralgia, and Hyperlipidemia. Depression In light of its recent approval in Canada and the US, esketamine nasal spray (Spravato) has been added to the Depression Augmentation/Adjunctive therapy options. Highlights include: Approved by Health Canada for…
We are pleased to announce the addition of a new condition to our TreatGx medication decision support software. The Overactive Bladder treatment algorithm can now be accessed by all TreatGx users and includes pharmacotherapy options for adults with overactive bladder, including…
All TreatGx users now have access to the updated treatment algorithms for Atrial Fibrillation – Anticoagulation and Anxiety – Social Anxiety Disorder. Atrial Fibrillation – Anticoagulation The updated atrial fibrillation anticoagulation algorithm provides a streamlined approach to medication options when initiating or switching between…
Dr. James Lu co-founded population genomics company Helix in 2015, where he leads the research, regulatory policy and bioinformatics teams. He oversees the teams that develop and validate the science and technology behind Helix’s solution, including Helix’s next generation sequencing lab. Dr. Lu also works with Helix’s partners to design and execute population-scale genomic research initiatives.
GenXys, a health tech company focused on pharmacogenetic enhanced prescribing automation software, is pleased to announce that it has closed an oversubscribed seed round at $3 million. Led by Green Shield Canada, (GSC), with key investors including TELUS Ventures, Esplanade Ventures, Nimbus Synergies, and the Business Development Bank of Canada (BDC Capital).
TreatGx has undergone some exciting changes to make it easier and faster than ever to generate personalized medication treatment options. As a result of this update, you may notice that some question categories may display as red and require you to…
We spoke to Erik Abel, former Director of Clinical Transformation, Highmark Health about his experiences in making system-level changes in healthcare and how well-designed clinical decision support systems (CDSS) can fit into that change. He started out in pharmacy as a specialist in cardiac surgery and mechanical circulatory support. At the Ohio State University medical center, he worked on some of their first efforts into alternative payment models. They realized that technology was a key component for driving the changes that they wanted to make. Here are some of the highlights from our discussion.
All TreatGx users now have access to the updated treatment algorithms for Gastroesophageal Reflux Disease (GERD) and H. pylori Eradication. The GERD algorithm provides pharmacotherapy options for adults with mild/intermittent or moderate-severe GERD symptoms, and treatment options for pregnancy. The H. pylori Eradication algorithm provides…